Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
LOSH J MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director J. Michael Losh had 7,880 restricted stock units credited to the J. Michael Losh Irrevocable Qualified Annuity Trust #7. These units were issued as deferred stock units in lieu of cash fees for board service and are tied to the closing share price on the last day of the quarter.
Each restricted stock unit represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after Mr. Losh’s service on the board ends or upon an earlier change in control. Following this grant, the trust is reported as holding 90,363 deferred/restricted stock units in total, all indirectly associated with Mr. Losh.
Amesite Inc. director Parmer George exercised restricted stock units into common shares, increasing his direct equity stake. On March 7, 2026, 41,322 restricted stock units converted into 41,322 shares of Amesite common stock at a stated price of $0.00 per share. Following the transaction, George directly owned 323,060 shares of common stock. The reported restricted stock units were originally granted on March 7, 2025 and vested on March 7, 2026, with each unit representing a right to receive one share of common stock or its cash equivalent. No open-market purchases or sales were reported in this filing.
Amesite Inc. director Barbie Brewer exercised restricted stock units that had vested into common shares. On March 7, 2026, she converted 41,322 restricted stock units into 41,322 shares of Amesite common stock at a stated price of $0.00 per share as part of her equity compensation.
These restricted stock units were originally granted on March 7, 2025 and vested on March 7, 2026. Following the conversion, Brewer directly holds 135,977 shares of Amesite common stock, and there are no remaining derivative positions from this RSU grant disclosed in the filing.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, exercised 41,322 restricted stock units into the same number of Amesite common shares on March 7, 2026. These RSUs were granted on March 7, 2025 and vested one year later. Following the transaction, the trust holds 143,699 shares of Amesite common stock indirectly. This is a compensation-related derivative exercise with no open-market buying or selling disclosed.
Amesite Inc. director J. Michael Losh reported a routine equity compensation event involving restricted stock units held through a trust. On March 7, 2026, the J. Michael Losh Irrevocable Qualified Annuity Trust #7 exercised 41,322 restricted stock units granted on March 7, 2025, converting them into 41,322 shares of Amesite common stock at no cash exercise price. Following the conversion, the trust holds 138,200 shares of common stock indirectly on behalf of Losh. Each restricted stock unit represented a right to receive one share of Amesite common stock or its cash equivalent upon vesting.
Amesite Inc. director J. Michael Losh reported an equity compensation award made through an associated trust. On February 6, 2026, the J. Michael Losh Irrevocable Qualified Annuity Trust #7 received 49,751 restricted stock units (RSUs) of Amesite at a price of $0 per unit.
Each RSU represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The RSUs fully vest on the first anniversary of the grant date, after which the trust will be entitled to the underlying shares or cash value.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, reported an award of 49,751 restricted stock units (RSUs) of Amesite Inc. on February 6, 2026, at a price of $0 per unit.
Each RSU represents a contingent right to receive one share of Amesite common stock and/or the cash equivalent of one share. The RSUs fully vest on the first anniversary of the grant date, and the trust holds 49,751 derivative securities after this transaction.
Amesite Inc. director George Parmer reported an equity award in the form of derivative securities. On February 6, 2026, he received 49,751 restricted stock units (RSUs) at a price of $0 per unit. Each RSU represents a contingent right to receive one share of AMST common stock and/or the cash equivalent.
The RSUs fully vest on the first anniversary of the grant date, and Parmer now directly holds 49,751 derivative securities linked to Amesite common stock as a result of this award.
Amesite Inc. director Barbie Brewer received a grant of 49,751 restricted stock units (RSUs) on February 6, 2026. Each RSU represents a right to receive one share of Amesite common stock or its cash equivalent. The RSUs fully vest on the first anniversary of the grant date, giving Brewer potential future ownership if service-based conditions are satisfied.
Amesite Inc. reports sharply higher revenue but continues to operate at a loss and faces going concern and listing risks. Net revenue for the six months ended December 31, 2025 rose to $202,346 from $24,010 a year earlier, with the quarter at $108,050 versus $12,760.
Cost-cutting reduced the six‑month net loss to about $1.37 million from $2.03 million, as general and administrative, technology, and sales and marketing expenses all declined. Cash, cash equivalents, and restricted cash fell to $1.27 million from $2.43 million at June 30, 2025, as operations used over $1.03 million of cash.
Management states there is substantial doubt about Amesite’s ability to continue as a going concern absent additional financing, and plans may include further common stock offerings. The company also discloses a Nasdaq deficiency notice for not meeting the $2.5 million stockholders’ equity requirement, with an extension to April 27, 2026 to regain compliance.